Troy Wichterman Sells 956 Shares of BioLife Solutions, Inc. (NASDAQ:BLFS) Stock

BioLife Solutions, Inc. (NASDAQ:BLFS) CFO Troy Wichterman sold 956 shares of the business’s stock in a transaction on Thursday, April 18th. The shares were sold at an average price of $15.31, for a total transaction of $14,636.36. Following the completion of the sale, the chief financial officer now directly owns 126,658 shares of the company’s stock, valued at $1,939,133.98. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Troy Wichterman also recently made the following trade(s):

• On Thursday, March 21st, Troy Wichterman sold 520 shares of BioLife Solutions stock. The shares were sold at an average price of $17.83, for a total transaction of $9,271.60.
• On Monday, March 11th, Troy Wichterman sold 361 shares of BioLife Solutions stock. The shares were sold at an average price of $17.42, for a total transaction of $6,288.62.
• On Wednesday, February 21st, Troy Wichterman sold 97 shares of BioLife Solutions stock. The shares were sold at an average price of $17.35, for a total transaction of $1,682.95.

BioLife Solutions Trading Down 1.9 %

NASDAQ BLFS opened at $16.86 on Friday. BioLife Solutions, Inc. has a one year low of $8.92 and a one year high of $24.50. The company has a debt-to-equity ratio of 0.06, a quick ratio of 1.83 and a current ratio of 2.86. The firm’s fifty day moving average is $17.38 and its two-hundred day moving average is $15.42. The firm has a market cap of $763.76 million, a PE ratio of -11.09 and a beta of 1.67.

BioLife Solutions (NASDAQ:BLFS) last issued its quarterly earnings results on Thursday, February 29th. The medical equipment provider reported ($0.22) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.02. BioLife Solutions had a negative net margin of 46.37% and a negative return on equity of 13.36%. The business had revenue of $32.73 million for the quarter, compared to analyst estimates of $32.70 million. Analysts expect that BioLife Solutions, Inc. will post -0.6 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Goldman Sachs Group Inc. increased its stake in shares of BioLife Solutions by 1,038.9% during the fourth quarter. Goldman Sachs Group Inc. now owns 2,401,899 shares of the medical equipment provider’s stock worth $39,031,000 after acquiring an additional 2,191,002 shares during the period. Granahan Investment Management LLC grew its position in BioLife Solutions by 22.8% during the fourth quarter. Granahan Investment Management LLC now owns 1,292,675 shares of the medical equipment provider’s stock worth $21,006,000 after buying an additional 240,001 shares during the period. Invesco Ltd. grew its position in BioLife Solutions by 6.5% during the third quarter. Invesco Ltd. now owns 1,052,065 shares of the medical equipment provider’s stock worth $14,529,000 after buying an additional 64,475 shares during the period. William Blair Investment Management LLC acquired a new position in BioLife Solutions during the third quarter worth about $9,335,000. Finally, New York State Common Retirement Fund grew its position in BioLife Solutions by 11.9% during the third quarter. New York State Common Retirement Fund now owns 419,618 shares of the medical equipment provider’s stock worth $5,795,000 after buying an additional 44,714 shares during the period. 93.24% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Separately, Jefferies Financial Group assumed coverage on shares of BioLife Solutions in a research note on Thursday, April 4th. They issued a “buy” rating and a $22.00 price objective on the stock. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $23.40.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.